AzTrials
AzTrials

Newborn; InfectionNCT03183531

New Protocol for Febrile Neonate Management

An observational study of Newborn; Infection and Newborn Sepsis, run by Sisli Hamidiye Etfal Training and Research Hospital at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of present study was to evaluate clinical and laboratory characteristics of febrile neonate and describe the incidence of SBI in febrile neonates. Secondarly investigators aimed to test usefulness of major protocols and new protocol in evaluating only febrile neonate. Read more about this study

Who is it for?
Ages 1 day to 28 days
Conditions the study is for
Newborn; Infection, Newborn Sepsis
What is being tested?
C reactive protein
How many people
328 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Jan 2011to 31 Mar 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 day to 28 days
  • All sexes
  • No healthy volunteers
  • Child

Study population: newborn babies admitted to hospital with fever

Who may be able to join

  • All neonates who were admitted to the neonatal intensive care unit with a rectal temperature of ≥38°C (documented at the time of medical evaluation) were eligible for the participation in this study.

Who cannot join

  • The exclusion criteria were gestational age less than 35 weeks, who refused to participate in the study, chromosome abnormality (e.g., trisomy 21, 18), the presence of a chronic disease, congenital malformations (cyanotic heart disease, meningomyelocele), admission to pediatric surgery, started on antibiotics before admission, and incomplete records.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Sisli Etfal Education and Research Hospital

    Istanbul, 34250

Other trials in Turkey (Türkiye)

About this study

Official title: New Protocol for Identification of Serious Bacterial Infection in Febrile Newborn

The objective of present study was to evaluate clinical and laboratory characteristics of febrile neonate and describe the incidence of SBI in febrile neonates. Secondarly investigators aimed to test usefulness of major protocols and new protocol in evaluating only febrile neonate.

Read the detailed description

This was a prospective observational cohort study, conducted between January 2011 and December 2015 (5 years) at Sisli Hamidiye Etfal Hospital, a tertiary care university-affiliated medical center in Istanbul. Written informed consent was obtained from the parents of all infants enrolled in the study before inclusion. The study protocol was approved by the local ethic committee.

Study population All neonates who were admitted to the neonatal intensive care unit with a rectal temperature of ≥38°C (documented at the time of medical evaluation) were eligible for the participation in this study. The exclusion criteria were gestational age less than 35 weeks, who refused to participate in the study, chromosome abnormality (e.g., trisomy 21, 18), the presence of a chronic disease, congenital malformations (cyanotic heart disease, meningomyelocele), admission to pediatric surgery, started on antibiotics before admission, and incomplete records. A complete history was obtained from the parents of infants, and a specialist in neonatology carried out a physical examination for localizing the source of the fever in all infants.

Data collection The data obtained for all infants included: demographic information (age at admission, gender, and birth weight), general assessment (well or sick-appearing), medical history, physical examination findings, laboratory test results, and final diagnosis. Laboratory investigations including complete blood count, CRP level, blood chemistry and culture, urine sample analysis and culture (obtained by bladder catheterization), and cerebrospinal fluid sample analysis and culture, were carried out. In the presence of respiratory symptoms or signs, chest radiography was performed. Lumbar puncture was performed according to the ward's policy, which is required for every infant if neurologic findings are positive or without the focus on fever. Stool specimens were obtained when a history of diarrhea was noted and sent for white blood cell analysis and bacterial culture. Other tests were conducted as necessary. Skin, soft tissue, and ear infections were diagnosed by physical examination.

Definition of SBI An episode of SBI was defined as (A) the growth of a known pathogenic bacteria in one or more of cultures (bacteremia, meningitis, osteomyelitis, suppurative arthritis, urinary tract infection, bacterial enteritis, and pneumonia), (B) any disease commonly associated with bacterial pathogens including pneumonia, acute otitis media, suppurative arthritis, osteomyelitis, and soft-tissue infections (cellulitis, abscess, mastitis, and omphalitis). Pneumonia was defined as a new discrete infiltration on the chest film, which was confirmed by an attending pediatric radiologist with the presence of typical clinical signs and symptoms.

All specimens for culture were evaluated by standard microbiological methods. No specimens were processed for viral cultures. The blood culture isolates were considered pathogenic if the organism was known to cause disease in healthy infants. UTI (urinary tract infection) was defined as the isolation of >104 CFU/mL of urine of a single pathogen by catheterization. A positive urine analysis was defined by a positive test for leucocyte esterase or nitrite by the dipstick method or leukocyte ≥10 cells/mm3 in uncentrifuged urine. Methods of viral agent evaluation: in infants with viral respiratory symptoms and complaints (a runny nose, sneezing, coughing), the presence of RSV-Ag (rapid immunochromatographic test produced by Prima lab SA, Switzerland), and influenza-Ag (Immunoassay test produced by Dalian Rongbang Medical Healthy Devices, Spain) were assessed from nasopharyngeal secretions. The body weight of the subjects was taken on admission and weight loss was assessed according to the birth weight. The proportion of weight loss more than twelve percent of birth weight was considered as dehydration.

All patients were hospitalized and prophylactic antibiotic therapy was started and continued for at least 72 hours (cases diagnosed only with dehydration did not receive antibiotics).

Newly proposed protocol (Sisli Etfal) includes:

(1) Unremarkable medical history (no perinatal antibiotics, no underlying disease, not hospitalized longer than the mother), (2) Good appearance, (3) No focal physical signs of infection, (4) CRP level < 1 mg/dl, (5) WBC 5000-15000 counts/mm3 and band/neutrophil ratio (I/T) <0.2, (6) A normal urine analysis.

The infants with all these criteria were considered to have a low risk for SBI. All infants were classified at low-risk by the criteria of Rochester, Boston, Philadelphia and Sisli Etfal protocols. The criteria of four protocols are presented in Table 1.

Statistical analysis The data were analyzed by using SPSS version 15.0 (SPSS, Chicago, IL, USA). Categorical variables are reported as percentages, and normally distributed data are expressed as mean±SD. Statistical comparisons between two groups performed with Student's t-test for normally distributed data, Mann-Whitney U test for non-normally distributed data, and chi-square test for all numerical and categorical values. The positive predictive value (PPV) for SBI of at least one abnormal criteria and the NPV for SBI of the low-risk criteria, in combination, were calculated by the standard statistical formula. All patients were evaluated according to the Boston, Philadelphia, Rochester and Sisli Etfal protocols, and the results were compared for sensitivity, specificity, NPV, PPV, and accuracy values. For predicting SBI, the serum levels of CRP and WBC count were subjected to receiver operating characteristics (ROC) curve analysis. The results were considered to be significant if analysis yielded p<0.05.

Being tested
C reactive protein
Medical subject headings
Infections, Neonatal Sepsis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • C reactive proteinDiagnostic test

    Addition of C-reactive protein test for management strategies to follow-up febrile neonates in outpatient.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of characteristics of febrile neonate and describe the incidence of SBI in febrile neonates.

    All febrile neonate admitted and evaluated for SBI. An episode of SBI was defined as (A) the growth of a known pathogenic bacteria in one or more of cultures (bacteremia, meningitis, osteomyelitis, suppurative arthritis, urinary tract infection, bacterial enteritis, and pneumonia), (B) any disease commonly associated with bacterial pathogens including pneumonia, acute otitis media, suppurative arthritis, osteomyelitis, and soft-tissue infections (cellulitis, abscess, mastitis, and omphalitis). Pneumonia was defined as a new discrete infiltration on the chest film, which was confirmed by an attending pediatric radiologist with the presence of typical clinical signs and symptoms.

    Measured: 5 years

  2. Usefulness of major protocols and new protocol in evaluating only febrile neonate.

    All infants were classified at low-risk by the criteria of Rochester, Boston, Philadelphia and new created Sisli Etfal protocols.

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jun 2017
  2. Study start1 Jan 2011
  3. Primary completion31 Dec 2015
  4. Study completion31 Mar 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Retrospective
Enrolment
328 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03183531
Sponsor's protocol ID
sislietfal.06.2017
Status last verified
Jun 2017
First submitted
6 Jun 2017
Last updated
12 Jun 2017
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Newborn; Infection and Newborn Sepsis, run by Sisli Hamidiye Etfal Training and Research Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Jun 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of characteristics of febrile neonate and describe the incidence of SBI in febrile neonates. (time frame: 5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2017.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in